Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

NCT03061214 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

868

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: Semaglutide 0.5 mg
DRUG: Semaglutide 1.0 mg
DRUG: Sitagliptin placebo
DRUG: Sitagliptin
DRUG: Semaglutide placebo 0.5 mg
DRUG: Semaglutide placebo 1.0 mg

Sponsor

Novo Nordisk A/S